Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biondvax Pharma ADR
(NQ:
BVXV
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biondvax Pharma ADR
< Previous
1
2
3
4
5
Next >
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
April 17, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Biden Signs Measure to End National COVID-19 Emergency
April 17, 2023
Via
Investor Brand Network
Topics
Government
Exposures
COVID-19
Political
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities
April 14, 2023
Via
Investor Brand Network
Eczema or Asthma Predisposes Individuals to Osteoarthritis
April 04, 2023
Via
Investor Brand Network
New Approach Could Boost Current Asthma Medication Efficacy
March 23, 2023
Via
Investor Brand Network
Risk Factors of Age-Related Macular Degeneration
February 27, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
April 14, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
April 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections
March 29, 2023
Via
Investor Brand Network
Topics
Climate Change
Exposures
Climate
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
March 24, 2023
Via
Investor Brand Network
Exposures
COVID-19
Japan to Categorize COVID-19 as Common Infectious Illness
March 17, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring
March 16, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax to Present at BIO-Europe Spring
March 16, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Study Shows Air Pollution in Urban Areas Worsens Lung Function in Kids
March 13, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders
March 13, 2023
Via
Investor Brand Network
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
March 06, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Climate Change Heightening Risk of Global Infectious Illnesses
March 06, 2023
Via
Investor Brand Network
Topics
Climate Change
Exposures
COVID-19
Climate
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series
March 06, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants
March 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies
March 02, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants
February 24, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal
February 22, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages
February 15, 2023
Via
Investor Brand Network
Exposures
COVID-19
Study Finds Common Fatty Acid May Increase Pain, Temperature Sensitivity in Psoriasis
February 15, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
February 13, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth
February 08, 2023
Via
Investor Brand Network
New Model Sheds Light on Patterns of Infectious Illnesses
February 07, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target
February 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
February 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
February 02, 2023
Via
Investor Brand Network
Exposures
COVID-19
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.